NCT05328557View on ClinicalTrials.gov

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

CUG252

CUG252 will be administered by subcutaneous (SC) injection

DRUG

Placebo

Placebo will be administered by subcutaneous (SC) injection

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

Sponsors

Lead Sponsor

Cugene Inc.
All Listed Sponsors
lead

Cugene Inc.

INDUSTRY

NCT05328557 - A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter